PMID: 12231267Sep 17, 2002Paper

Costs and outcomes of risperidone treatment in schizophrenia in the Czech Republic

European Psychiatry : the Journal of the Association of European Psychiatrists
L Hosák, R Bahbouh

Abstract

The increasing cost of pharmaceuticals in the Czech Republic has led to restrictions on the prescription of more expensive atypical antipsychotics. The aim of the study was to compare the costs and outcomes of using risperidone versus classical neuroleptics in treatment of schizophrenia in order to see if there was any cost advantage in restricting use of more recent antipsychotics. Sixty-seven patients (39 women) with a mean age of 34.6 years (S.D. = 9.74) suffering from schizophrenia or schizoaffective disorder were treated with risperidone while 67 patients (39 women) with the same diagnoses with a mean age of 35.7 years (S.D. = 9.91) received standard neuroleptics. Yearly direct medical costs and outcomes (indicated by the average Global Assessment of Functioning score) were assessed retrospectively in an open, intent-to-treat study by abstracting psychiatric outpatient charts. The outcomes were not significantly different between the treatment groups while the risperidone treatment was significantly more expensive than the therapy with standard neuroleptics. This result which appears to be inconsistent with the literature was caused by the cheap labor force in the Czech Republic. The difference between the followed treatme...Continue Reading

References

Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B GallhoferH Gruppe
Jan 1, 1997·Acta Psychiatrica Scandinavica·A RossiM Casacchia
Oct 1, 1996·Journal of Clinical Pharmacy and Therapeutics·I R de OliveiraJ Bacaltchuk
Jun 1, 1997·The American Journal of Psychiatry·M F GreenJ Mintz
Sep 1, 1997·Psychiatric Services : a Journal of the American Psychiatric Association·G VialeB J Lawrence
Jan 1, 1997·European Archives of Psychiatry and Clinical Neuroscience·H J MöllerH Schubert
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·M Knapp
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Dec 30, 1998·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·G ChouinardK I Singh
Feb 25, 1999·Psychiatric Services : a Journal of the American Psychiatric Association·M J SchillerW A Hargreaves
Mar 29, 2008·Clinical Drug Investigation·S MorrisA McGuire

❮ Previous
Next ❯

Citations

Apr 16, 2014·Current Medical Research and Opinion·Marie-Hélène LafeuillePatrick Lefebvre
Jan 9, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Linda M DaviesUNKNOWN CUTLASS Team
May 13, 2005·Journal of Psychopharmacology·Christos Christodoulou, Chryssanthi Kalaitzi
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Adib EssaliJohn Rathbone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Progress in Neuro-psychopharmacology & Biological Psychiatry
Thomas L SchwartzPrakash S Masand
The British Journal of Psychiatry : the Journal of Mental Science
R W Kerwin, K J Aitchison
© 2021 Meta ULC. All rights reserved